We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s Pre-Approval Inspections Fell by More Than 50 Percent in 2021, Report Says
FDA’s Pre-Approval Inspections Fell by More Than 50 Percent in 2021, Report Says
The FDA’s Office of Pharmaceutical Quality (OPQ) used alternative tools because of the ongoing pandemic that reduced the number of facilities needing pre-approval inspections by more than 50 percent in fiscal 2021, OPQ said in its annual report released yesterday.